Recombinant Mouse VSIG3 Fc Chimera Protein, CF

Recombinant Mouse VSIG3 Fc Chimera (Catalog # 9367-VS)inhibits anti-CD3 antibody induced IL-17 secretion in human PBMC.The ED50 for this effect is 1-5 μg/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse VSIG3 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-17 secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 1-5 μg/mL
• Source: Mouse myeloma cell line, NS0-derived mouse VSIG3 protein
  

  Mouse VSIG3 (Leu23-Gly245) Accession # P0C673	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: P0C673
• N-terminal Sequence: Leu23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 51 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-68 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse VSIG3 Fc Chimera Protein, CF

• Brain and testis-specific immunoglobulin superfamily protein
• BTIGSF
• BT-IgSF
• cancer/testis antigen 119
• CT119
• CXADR like 1
• CXADRL1
• IGSF11
• Igsf13
• immunoglobulin superfamily member 11
• immunoglobulin superfamily, member 11
• MGC35227
• V-set and immunoglobulin domain containing 3
• V-set and immunoglobulin domain-containing protein 3
• VSIG3
• VSIG3brain and testis-specific immunoglobin superfamily protein

Background

VSIG3 (V-­set and immunoglobulin domain containing 3) also known as IgSF11 (Immunoglobulin superfamily member 11), is an approximately 50 kDa type I transmembrane adhesion protein of the Ig superfamily. Mature mouse VSIG3 consists of a 218 amino acid (aa) extracellular domain (ECD) containing one V-type Ig-like domain and one Ig-like C2-type domain, a 21 aa transmembrane domain, and a 167 aa cytoplasmic domain. Within the ECD, mouse VSIG3 shares 95% and 98% aa identity with human and rat VSIG3, respectively. VSIG3 is expressed on epithelial and endothelial cells, neurons and glial cells, and platelets (1). It localizes to epithelial tight junctions and mediates homophilic in trans cell adhesion (1-3). VSIG3 also localizes to neuronal postsynaptic densities where it recruits the GluA1 and GluA2 subunits of AMPA receptors and supports excitatory synaptic transmission (4). In zebrafish, VSIG3 is expressed in melanophores and their precursors and plays a role in the development and patterning of pigment cells (5). VSIG-3 expression is elevated in colorectal cancers and hepatocellular carcinomas as well as
intestinal-type gastric cancers. Suppression of VSIG-3 by siRNA retarded the growth of gastric cancer cells, suggesting that VSIG-3 is a good candidate for gastric cancer immunotherapy (6).

1. Raschperger, E. et al. (2004) J. Biol. Chem. 279:796.
2. Katoh, M. and M. Katoh (2003) Int. J. Oncol. 23:525.
3. Harada, H. et al. (2005) J. Cell. Physiol. 204:919.
4. Jang, S. et al. (2016) Nat. Neurosci. 19:84.
5. Eom, D.S. et al. (2012) PLoS Genet. 8:e1002899.
6. Watanabe T, et al. (2005) Cancer Sci. 96:498.

Bioinformatics

• Uniprot:
  • P0C673()